429 related articles for article (PubMed ID: 27832476)
1. Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.
Liu M; Huang YY; Hsu S; Kass JS
CNS Drugs; 2016 Dec; 30(12):1149-1168. PubMed ID: 27832476
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Adverse Effects of Neurologic Medications.
Bahrani E; Nunneley CE; Hsu S; Kass JS
CNS Drugs; 2016 Mar; 30(3):245-67. PubMed ID: 26914914
[TBL] [Abstract][Full Text] [Related]
3. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
4. Adverse events from systemic therapies for psoriasis are common in clinical practice.
Pearce DJ; Higgins KB; Stealey KH; Balkrishnan R; Crane MM; Camacho F; Fleischer AB; Feldman SR
J Dermatolog Treat; 2006; 17(5):288-93. PubMed ID: 17092859
[TBL] [Abstract][Full Text] [Related]
5. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.
Murase JE; Heller MM; Butler DC
J Am Acad Dermatol; 2014 Mar; 70(3):401.e1-14; quiz 415. PubMed ID: 24528911
[TBL] [Abstract][Full Text] [Related]
6. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation.
Butler DC; Heller MM; Murase JE
J Am Acad Dermatol; 2014 Mar; 70(3):417.e1-10; quiz 427. PubMed ID: 24528912
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of acne medications: recognition and management.
Oudenhoven MD; Kinney MA; McShane DB; Burkhart CN; Morrell DS
Am J Clin Dermatol; 2015 Aug; 16(4):231-242. PubMed ID: 25896771
[TBL] [Abstract][Full Text] [Related]
8. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review.
Zakhem GA; Motosko CC; Mu EW; Ho RS
J Am Acad Dermatol; 2019 Apr; 80(4):957-969. PubMed ID: 30287313
[TBL] [Abstract][Full Text] [Related]
9. Neuro-ophthalmologic side-effects of systemic medications.
Pula JH; Kao AM; Kattah JC
Curr Opin Ophthalmol; 2013 Nov; 24(6):540-9. PubMed ID: 24100367
[TBL] [Abstract][Full Text] [Related]
10. Are excipients really inert ingredients? A review of adverse reactions to excipients in oral dermatologic medications in Canada.
Noiles K; Vender R
J Cutan Med Surg; 2010; 14(3):105-14. PubMed ID: 20487670
[TBL] [Abstract][Full Text] [Related]
11. Managing nonteratogenic adverse reactions to isotretinoin treatment for acne vulgaris.
Reilly BK; Ritsema TS
JAAPA; 2015 Jul; 28(7):34-9. PubMed ID: 26107793
[TBL] [Abstract][Full Text] [Related]
12. A boxed warning for inadequate psoriasis treatment.
Kagha KC; Blauvelt A; Anderson KL; Leonardi CL; Feldman SR
Cutis; 2016 Sep; 98(3):206-207. PubMed ID: 27814414
[No Abstract] [Full Text] [Related]
13. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
14. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
15. Current systemic therapies for psoriasis: where are we now?
Yamauchi PS; Rizk D; Kormeili T; Patnaik R; Lowe NJ
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S66-77. PubMed ID: 12894129
[TBL] [Abstract][Full Text] [Related]
16. [Off-label use].
Fritz K; Augustin M; John SM
Hautarzt; 2013 Oct; 64(10):727. PubMed ID: 24150819
[No Abstract] [Full Text] [Related]
17. Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology.
Bellodi-Schmidt F; Shah KN
Pediatr Dermatol; 2016; 33(1):18-27. PubMed ID: 26607958
[TBL] [Abstract][Full Text] [Related]
18. Advances in Psoriasis.
Smith J; Cline A; Feldman SR
South Med J; 2017 Jan; 110(1):65-75. PubMed ID: 28052180
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapy in erythrodermic and pustular psoriasis.
Levin EC; Debbaneh M; Koo J; Liao W
J Drugs Dermatol; 2014 Mar; 13(3):342-54. PubMed ID: 24595581
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
